Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E

Inclusion Criteria Patients must have: Enrollment on protocol RV-43 (AZT resistance study). Development of a primary RV-43 study endpoint-opportunistic infection. HIV isolate with an AZT IC50 > 50 times that of the sensitive type strain. Able to swallow tablets without difficulty. Normal QTc interval on EKG. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Clinically significant hypersensitivity to piperazine type drugs (Antepar, Stelazine). Severe uncontrollable diarrhea or vomiting or known malabsorption. Symptomatic hyperlipidemia. Concurrent Medication: Excluded: Other experimental drugs. AZT, ddI, ddC, foscarnet, immunomodulators or other agents with primary antiretroviral activity (exemptions by principal investigator permitted). Patients with the following prior conditions are excluded: History of clinically significant cardiovascular disease or nervous system or muscle disease, including seizures, peripheral neuropathy, dementia, or motor dysfunction. Prior Medication: Excluded: Experimental drugs within 4 weeks prior to study entry.